Clarapath launches TrimStar Pro robotic microtomy system
May 5, 2026—Clarapath launched TrimStar Pro, an FDA-registered facing and trimming solution designed to help histology laboratories take a step toward automation.
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Atellica TSTII Testosterone assay gets CDC HoSt-TT certification
May 4, 2026—Siemens Healthineers’ Atellica IM Testosterone II assay has achieved certification through the Centers for Disease Control and Prevention hormone standardization program for total testosterone, confirming that the Atellica IM TSTII immunoassay’s test results are equivalent to high-performance liquid chromatography coupled with tandem mass spectrometry.
Archimed Diagnostics, La Caisse acquire Stago
May 1, 2026—Archimed Diagnostics, part of private equity health care firm Archimed, has acquired Stago, with global investment group La Caisse participating as a minority shareholder.
Project Santa Fe Foundation partners with Vivica
April 24, 2026—Clinical Lab 2.0, an initiative of Project Santa Fe Foundation, is partnering with Life Data Lab, developer of Vivica LabReports, a laboratory platform that enables clinical labs to identify potential gaps in patient care (per provider request).
Omnia Inventa introduces LNL300 for lymph node retrieval
April 23, 2026—Omnia Inventa Medical has introduced the Lymph Node Locator 300, an FDA class I, 510(k)-exempt device designed to standardize lymph node retrieval from fatty tissue in oncologic specimens.
PathAI, MedStar Health partner to deploy AISight Dx
April 20, 2026—PathAI and MedStar Health announced a multiyear strategic collaboration to deploy PathAI’s AISight Dx digital pathology platform and AI algorithm products, including PathAI’s ArtifactDetect and TumorDetect, across MedStar’s network.
Labcorp launches FDA-cleared fentanyl test
April 16, 2026—Labcorp launched the Labcorp Fentanyl Urine Visual Test.
Streck launches MDx-Chex for respiratory low-plex testing
April 15, 2026—Streck released MDx-Chex for RLP, a ready-to-use, full-process molecular quality control designed for respiratory low-plex assay verification.
Telcor acquires AI workflow platform Sample Healthcare
April 10, 2026—Telcor has acquired Sample Healthcare, an AI workflow platform designed to execute revenue cycle and clinical operations workflows.
Streck releases MDx-Chex controls for sexual health testing
April 1, 2026—Streck has launched MDx-Chex for CT/NG/TV and MDx-Chex for MVP (multiplex vaginal panel) controls for research use only.